Phosphodiesterase III inhibitor olprinone chlorate is not significantly removed by continuous venovenous hemodiafiltration.
The study objective was to determine whether a phosphodiesterase III inhibitor, olprinone chlorate, is effectively removed by continuous venovenous hemodiafiltration (CVVHDF) in a patient with cardiac and renal failure. The patient was a 73 year old man who had undergone coronary artery bypass grafting for ischemic heart disease and who developed cardiac and renal failure postoperatively. A 0.2 microg/kg per minute dosage of olprinone chlorate was administered intravenously for 120 minutes while the patient was treated with CVVHDF. Samples from the arterial and venous blood catheters and those from the ultradiafiltrate for 12 hours were collected to calculate pharmacokinetic parameters and clearance of hemodiafiltration. The calculated parameters were as follows: half-life of elimination phase: 4.96 hours; total clearance 3.40 ml/min per kg. The clearance of CVVHDF was 0.33 ml/min per kg. The olprinone chlorate clearance of CVVHDF approximates only 10% of total clearance in this case. CVVHDF may not produce significant reduction in the serum olprinone chlorate level. It is recommended that the infusion dosage of olprinone chlorate should be reduced when given to patients with renal failure even if treated with CVVHDF.
Amenomori
H
H
Division of Intensive Care, Hokkaido University Hospital, Sapporo, Japan.
Sasaki
S
S
Hiraoka
K
K
Morimoto
Y
Y
Gando
S
S
Kemmotsu
O
O
D000368:Aged; D017583:Hemodiafiltration; D006801:Humans; D007093:Imidazoles / Q000302:isolation & purification* / Q000493:pharmacokinetics; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000302:isolation & purification*; D011728:Pyridones / Q000302:isolation & purification* / Q000493:pharmacokinetics
D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D011728:Pyridones; C059498:olprinone